Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
2026-04-29Read more
MagnetisMM-5
Phase 3 Clinical Trial Evaluating The Safety and Effectiveness of Elranatamab Alone and Combined with Daratumumab Compared to the Combination of Daratumumab, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Links
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.